November 18, 2016

Patients with moderate to severe rheumatoid arthritis experienced similar outcomes at 12 weeks when treated with either UCB’s Cimzia, or certolizumab pegol, or AbbVie’s Humira, or adalimumab, in a two-year comparative study published in The Lancet.